OmniAb, Inc. (OABI) Stock

OmniAb, Inc. (OABI) is a Technology stock trading at $2.34 (as of 2026-06-18), with a market capitalization of $391.43M and a trailing P/E of -5.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

OmniAb, Inc. is a biotechnology company that develops therapeutic antibody discovery technologies. Its OmniAb platform and related transgenic animal systems (including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, and OmniTaur) are used to generate antibodies with human sequences and support discovery and screening for partners developing human therapeutic candidates.

Valuation — source: SEC EDGAR (first-party)
Price	$2.34
Market Cap	$391.43M
P/E Ratio	-5.9
EV / EBITDA	-9.0
Price / Book	1.49
Price / Sales	13.53
DCF Value (model)	$-4.17
DCF Upside vs Price	-278.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$18.67M
Net Margin	-347.0%
Return on Equity	-20.7%
Current Ratio	4.80
Revenue Growth (YoY)	-29.3%
EPS Growth (YoY)	-6.6%
FCF Growth (YoY)	-10.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	4.73 (safe)

Valuation vs Sector & Industry
Stock P/E	-5.9
Sector P/E (Technology)	32.6
Industry P/E (Business Services)	27.1
vs Sector	-118.0%
vs Industry	-121.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Whitefort Capital Management, LP ($22.33M)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Business Services
CEO	Matthew W. Foehr
Employees	114
Country	US
IPO Date	2021-09-30

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.